EN DE
Watch Ortivus AB ser. B for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ortivus AB ser. B (ORTI-B) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Ortivus AB ser. B stock SEK 1.00, price SEK 1.05, that is 4.3% below the price, quality 32 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0000123085

OA Ortivus AB ser. B logo Thin data Nov 10, 2026

Ortivus AB ser. B

ORTI-B · ST
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value kr 1.00 · Fairly valued
Moderate debt
Quality 32/100
Weak Growth (revenue 5y −7.4 %/yr in SEK)
Loss-making · -23.4% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 10/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Ortivus AB ser. B for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 7.66 kr 0.9760 Fair Value kr 1.00 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.9760 – kr 7.66 · fair‑value band kr 0.7500 – kr 1.25 · the kr 1.05 price screens above the kr 1.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 6 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Ortivus AB ser. B in your weekly email

Every Wednesday you see whether Ortivus AB ser. B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ortivus AB (publ) develops and commercializes medical technology solutions and e-health for healthcare industry in Sweden and internationally.

Show moreShow less

The company offers MobiMed Monitor that monitor and shares vital signs and ECG; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed enRoute, a navigation, case management, and mass casualty management; MobiMed FleetCtrl, a a software application that regular controls, checklists, and documentation tailored for seamless fleet management; MobiMed Life, a heart safe solution.

It also provides emergency medical services, primary care, and rescue services. The company was founded in 1985 and is headquartered in Danderyd, Sweden. Ortivus AB (publ) is a subsidiary of Ponderus Invest AB.

Stock analysis

Ortivus AB ser. B (ORTI-B) currently trades at kr 1.05, while our estimate is kr 1.00, so the stock looks roughly fairly valued today (gap 4.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.7500 (bear) to kr 1.25 (bull), the price of kr 1.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Ortivus AB ser. B reported revenue of 73.4M SEK in FY2025 versus 94.3M SEK in FY2021, a compound −6.1%/yr. Reported net income was −21.9M SEK in FY2025.

Key figures

Market cap 92.6M SEK (≈ $9.4M) Micro · P/S ratio 1.36 · EPS (TTM) kr −0.2900 · Net margin −23.4% · Return on equity −2,201% · Return on assets (EBIT) −11.1% (5-year average) · Operating margin −31.8% · Revenue (TTM) 76.4M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −4%, ORTI-B screens cheaper than that median.

Fair Value

Bear kr 0.7500 Fair Value kr 1.00 Bull kr 1.25
Price kr 1.05 · Downside -4.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 35
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.4%
Start year 2020 (pandemic). Over 10 years: +0.1% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.6% (2020) → −19.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ORTI-B, get fair value alerts →

Compare Ortivus AB ser. B with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 196 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −4.3% · Above median
Profitability
Return on assets −30.8% · Bottom 25%
Net margin (12 months) −23.4% · Bottom 25%
Operating margin (12 months) −31.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −1.8% · Bottom 25%
Balance sheet
Debt / equity 0.80× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 4.13× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.21× · Cheapest 25%
PEG 0.50× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)28 · sector 21
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)60 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.08 $131.27 +46% vs ORTI-B
EssilorLuxottica Société anonyme EL €187.60 €196.22 +5% vs ORTI-B
Intuitive Surgical, Inc ISRG $450.04 $353.90 −21% vs ORTI-B
Medline Inc MDLN $40.91 $28.59 −30% vs ORTI-B
Alcon Inc ALC CHF 61.88 CHF 34.06 −45% vs ORTI-B
Becton, Dickinson and Company BDX $212.61 $97.80 −54% vs ORTI-B
Straumann Holding STMN CHF 106.85 CHF 45.50 −57% vs ORTI-B
West Pharmaceutical Services, Inc WST $412.55 $139.22 −66% vs ORTI-B
Sartorius Stedim Biotech S.A DIM €223.40 €54.82 −75% vs ORTI-B
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs ORTI-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ortivus AB ser. B: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ortivus AB ser. B Fair Value". https://www.fairvalue-calculator.com/stock/ORTI-B

Frequently asked questions

Is Ortivus AB ser. B (ORTI-B) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 1.00 versus a price of kr 1.05, about 4% lower (fairly valued).
What is the fair value of ORTI-B?
Our estimate for Ortivus AB ser. B is kr 1.00 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 1.05.
What is the quality score of ORTI-B?
Ortivus AB ser. B has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ortivus AB ser. B (ORTI-B)?
Our calculated price target is the estimate of kr 1.00 (as of Nov 10, 2026). Cautious scenario kr 0.7500, optimistic scenario kr 1.25. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Ortivus AB ser. B stock forecast for 2026?
Our estimate puts fair value at kr 1.00, about 4% lower versus a price of kr 1.05 (fairly valued). Cautious scenario kr 0.7500, optimistic scenario kr 1.25. The calculation is refreshed regularly with new filings.
What is the revenue of Ortivus AB ser. B (ORTI-B)?
Ortivus AB ser. B reported trailing-twelve-month revenue of about 76.4M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Ortivus AB ser. B (ORTI-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ortivus AB ser. B it is kr 1.00 per share (as of Nov 10, 2026), against a price of kr 1.05.
Is Ortivus AB ser. B stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ORTI-B trades above its calculated fair value: price kr 1.05, fair value kr 1.00, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORTI-B?
No. The price is what the market pays today (kr 1.05); the fair value is what the company's own numbers justify (kr 1.00). For Ortivus AB ser. B the two are kr 0.0450 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ortivus AB ser. B worth?
The market values Ortivus AB ser. B at about 92.6M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 1.05; our models calculate a fair value of kr 1.00 per share.
What do the bullish and bearish scenarios say about ORTI-B?
Our models span a range for Ortivus AB ser. B: cautious scenario kr 0.7500, base kr 1.00, optimistic kr 1.25 per share (as of Nov 10, 2026, price kr 1.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ORTI-B?
The PEG ratio of Ortivus AB ser. B is 0.50 (P/E divided by earnings growth, as of Nov 10, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Ortivus AB ser. B (ORTI-B)?
Balance-sheet figures for Ortivus AB ser. B (as of Nov 10, 2026): debt of 0.80 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ORTI-B from its 52-week high?
Ortivus AB ser. B trades at kr 1.05, about 49% below its 52-week high of kr 2.04 and at the low of kr 1.05 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.00 is for.
Which stocks are comparable to Ortivus AB ser. B?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ortivus AB ser. B stock attractive at the current price?
The data as of Nov 10, 2026: price kr 1.05, calculated fair value kr 1.00 (−4%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Ortivus AB ser. B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ortivus AB ser. B (ORTI-B)?
The closing price on Nov 10, 2026 was kr 1.05. Our estimate is kr 1.00, about 4% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ortivus AB ser. B right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Ortivus AB ser. B

How large is the market capitalisation of Ortivus AB ser. B (ORTI-B)?
The market capitalisation of Ortivus AB ser. B is 92.6M SEK (≈ $9.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ortivus AB ser. B (ORTI-B)?
The price-to-sales ratio of Ortivus AB ser. B is 1.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ortivus AB ser. B (ORTI-B)?
Earnings per share at Ortivus AB ser. B are kr −0.2900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ortivus AB ser. B (ORTI-B)?
The net margin of Ortivus AB ser. B is −23.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ortivus AB ser. B (ORTI-B)?
The return on equity (ROE) of Ortivus AB ser. B is −2,201% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ortivus AB ser. B (ORTI-B)?
On an EBIT basis the return on assets of Ortivus AB ser. B is −11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ortivus AB ser. B (ORTI-B)?
The operating margin of Ortivus AB ser. B is −31.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ortivus AB ser. B (ORTI-B)?
Revenue at Ortivus AB ser. B is growing −1.8% versus a year earlier (3y avg −11.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ortivus AB ser. B (ORTI-B)?
Earnings per share at Ortivus AB ser. B are growing −88.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ortivus AB ser. B (ORTI-B) generate?
The free cash flow of Ortivus AB ser. B is −25.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ortivus AB ser. B (ORTI-B) carry?
The net debt of Ortivus AB ser. B is 10.6M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ortivus AB ser. B in the live analysis

One click puts Ortivus AB ser. B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.